Parkinson's Disease Mechanisms and Treatments

This study shows that LRRK2 kinase mediates haloperidol-induced motor side effects in striatal neurons, suggesting LRRK2 as a target to reduce antipsychotic side effects.

The paper investigates the role of MHCII reduction in protecting mice from alpha-synuclein-induced degeneration and finds that it is insufficient, while showing epigenetic regulation of the Parkinson's HLA locus.

The paper quantifies viscoelastic properties of synapsin condensates in live cells and identifies α-synuclein's role in regulating their material state.

This paper prioritizes Parkinson's disease risk genes in GWAS loci using a polygenic priority score, identifying 46 genes with potential for therapeutic development.

JM-20 treatment in 6-OHDA lesioned rats reduces motor asymmetry and oxidative stress markers in the SNpc and striatum.

This study investigates how Ca2+ and Na+ ions affect alpha-synuclein aggregation and fibril polymorphism, revealing their distinct roles in modulating conformational dynamics and structural outcomes.

The paper identifies synaptic dysfunction in cholinergic projection neurons as an early indicator of Parkinsonism across multiple fly models and links it to olfactory dysfunction and dopaminergic decline.

The paper introduces a metric for measuring accumulated neurotoxicity of alpha-synuclein oligomers and finds that rapid fibril formation reduces toxicity, while impaired degradation increases it.

The paper integrates multi-modal data to identify shared molecular dysregulation across Parkinson's disease variants, finding common transcriptomic features in glial cells and potential involvement of ROBO signalling.

This study investigates how RNA affects alpha-synuclein phase separation, showing RNA induces morphological changes and promotes liquid-to-solid transition.

This study investigates the HLA locus in PSP patients, finding associations between specific HLA alleles and disease risk, suggesting an autoimmune mechanism.

The paper investigates dopaminergic and serotonergic changes in the subgenual cingulate cortex of dementia with Lewy bodies patients with and without depression, finding reduced dopaminergic innervation and markers in depressed cases.

This study shows that alpha-synuclein knockout in TG3 mice delays melanoma onset and slows tumor growth, with sex-dependent effects on DNA damage repair.

The paper identifies two novel peptides that protect C. elegans from paraquat-induced Parkinson's-like pathology by inhibiting reactive oxygen species, mitochondrial damage, and alpha-synuclein aggregation.

The paper examines longitudinal brain atrophy in early Parkinson's disease and healthy aging, finding accelerated atrophy in PD patients and cerebellar volume changes suggesting compensatory mechanisms.

The paper identifies a DNA methylation module in the substantia nigra associated with depressive symptoms in Parkinson's disease.

The paper shows that PINK1 accumulates on mitochondria under depolarisation, remains active, and can precondition subsequent PINK1 activation.

This study uses single-cell sequencing to analyze peripheral immune cell changes in Parkinson's disease patients, identifying key immune signatures and potential biomarkers.

The paper investigates sex differences in aSyn pathology progression in M83 mice using MRI and behavioral analysis, finding female resilience to neurodegeneration despite earlier motor symptom onset in males.

This study shows Rab27b enhances lysosomal function and reduces alpha-synuclein accumulation in neurons, suggesting it as a therapeutic target for synucleinopathies.

This study shows that systemic XPro1595, a TNF inhibitor, does not protect against -Syn-induced Parkinson's-like pathology in rats, despite being effective in other neurodegeneration models.

This study uses molecular rotors to detect and compare oligomer formation and conversion to amyloids in wild-type and two α-synuclein variants, revealing differences in aggregation kinetics.

This study shows that a Miro1 mutation causes mitochondrial dysfunction and dopaminergic neuron loss in both cell models and mice, supporting its role in Parkinson's disease.

This study shows that activating astrocytes in the dorsal striatum improves motor deficits in Parkinson's disease mice by enhancing their calcium activity and behavioral performance.

This study identifies SENP2-mediated N-terminal truncation of α-synuclein as a mechanism driving Lewy pathology propagation and suggests SENP2 as a therapeutic target.

This study examines how parkinsonism affects neuronal activity in the pre-SMA during movement preparation in non-human primates, finding disrupted modulation and reduced predictive encoding of reaction time.

The paper shows aging reduces mRNA expression of dopamine and glutamate markers in midbrain neurons of mice and humans, but not protein levels or cell numbers.

This study shows LRRK2 and PINK1 function in parallel neuroprotective pathways affecting ciliogenesis in Parkinson's disease, suggesting shared therapeutic targets.

This study examines how neuronal activity in the dorsolateral prefrontal cortex changes in parkinsonism using nonhuman primates and finds early impairment in task-related firing rates.

This study shows nicotine reduces α-synuclein pathology and behavioral deficits in mice induced by human α-synuclein pre-formed fibrils.